VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

Adenovirus vectors expressing Marburg virus glycoprotein CAdVa-Filoviruses (EbMarburg viruses) cAdVaxM(fus)
Vaccine Information Vaccine Information Vaccine Information
  • Vaccine Ontology ID: VO_0004118
  • Type: Recombinant vector vaccine
  • Antigen: Glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
  • GP from Marburg virus Ci67 gene engineering:
    • Type: Recombinant protein preparation
    • Description: This Ci67 GP gene was amplified by PCR, and subcloned to create MARV adenovirus vaccine targeted against the Ci67strain of MARV (Wang et al., 2006).
    • Detailed Gene Information: Click Here.
  • GP from Marburg virus Ravn gene engineering:
    • Type: Recombinant protein preparation
    • Description: This Ravn GP gene was amplified by PCR, and subcloned to create MARV adenovirus vaccine targeted against the Ci67strain of MARV (Wang et al., 2006).
    • Detailed Gene Information: Click Here.
  • GP gene engineering:
    • Type: Recombinant protein preparation
    • Description: This Musoke GP gene was amplified by PCR, and subcloned to create MARV adenovirus vaccine targeted against the Musoke strain of MARV (Wang et al., 2006).
    • Detailed Gene Information: Click Here.
  • Preparation: The Ci67 GP (Genbank accession number AF005735; Protein ID AAC40460.1; a.a. 1–681), Ravn GP (Genbank accession number AF005734; Protein ID AAC40459.1; a.a. 1–681), and Musoke GP (Genbank accession number DQ217792; Protein ID ABA87127; a.a. 1–681) genes were amplified by PCR. Each MARV antigen was subcloned into the pLAd and pRAd shuttle vectors to create a series of MARV adenovirus vaccines targeted against the Ci67, Ravn, and Musoke strains of MARV. All cAdVax vector genomes were based on a modified Ad5sub360 vector backbone, which contains deletions in E1, E3 and almost all E4 ORFs with the exception of ORF6 (Wang et al., 2006).
  • Virulence: Although Ad vectors have a high affinity for the liver and may potentially cause inflammation in the liver, there is not pathology indicative of inflammation or cytotoxicity as a result of vaccination in mice (Wang et al., 2006).
  • Vaccine Ontology ID: VO_0004645
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • GP gene engineering:
    • Type: Recombinant vector construction
    • Description: Novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
    • Detailed Gene Information: Click Here.
  • GP from Marburg virus Ravn gene engineering:
    • Type: Recombinant vector construction
    • Description: Novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
    • Detailed Gene Information: Click Here.
  • GP from Marburg virus Ci67 gene engineering:
    • Type: Recombinant vector construction
    • Description: Novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
    • Detailed Gene Information: Click Here.
  • Preparation: Three novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0004646
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • GP gene engineering:
    • Type: Recombinant vector construction
    • Description: Novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
    • Detailed Gene Information: Click Here.
  • GP from Marburg virus Ravn gene engineering:
    • Type: Recombinant vector construction
    • Description: Novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
    • Detailed Gene Information: Click Here.
  • GP from Marburg virus Ci67 gene engineering:
    • Type: Recombinant vector construction
    • Description: Novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
    • Detailed Gene Information: Click Here.
  • Preparation: Three novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response Host Response Host Response

Mouse Response

  • Host Strain: C57BL/6 mice
  • Vaccination Protocol: Four groups of 28 C57BL/6 mice were immunized intra-peritoneally (i.p.) at weeks 0, 4 and 8 with 1 × 108 pfu of either cAdVaxM(ci), cAdVaxM(ra), cAdVaxM(mu), or HC4 control vector prepared in 100 μl PBS/10% glycerol. HC4, an unrelated adenovirus-based Hepatitis C vaccine, served as a negative control vaccine. Four mice per group were sacrificed at weeks 2, 4, 6, 8, 10, 12, and 24 (Wang et al., 2006).
  • Persistence: The persistence of these three vaccine candidates in mice was not reported.
  • Immune Response: Immunization of mice with complex adenovirus (Ad)-based vaccine candidates (cAdVax vaccines) induced efficient production of both antibodies and cytotoxic T lymphocytes (CTL) specific to Musoke strain GP and Ci67 strain GP, respectively. Antibody responses were also cross-reactive across the MARV strains, but not cross-reactive to Ebola virus, a related filovirus (Wang et al., 2006).
  • Side Effects: Three 1 × 108 pfu doses of vaccine vector did not lead to any detectable toxicity in liver or spleen, so it appears to be safe (Wang et al., 2006).
  • Challenge Protocol: No challenge experiment was conducted.

Mouse Response

  • Vaccination Protocol: Immunization of mice with complex adenovirus (Ad)-based vaccine candidates (cAdVax vaccines) (Wang et al., 2006).
  • Vaccine Immune Response Type: VO_0003057
  • Efficacy: Vaccination led to efficient production of both antibodies and cytotoxic T lymphocytes (CTL) specific to Musoke strain GP and Ci67 strain GP, respectively. Antibody responses were also shown to be cross-reactive across the MARV strains, but not cross-reactive to Ebola virus, a related filovirus. Additionally, three 1 x 10(8)pfu doses of vaccine vector were demonstrated to be safe in mice, as this did not lead to any detectable toxicity in liver or spleen (Wang et al., 2006).

Mouse Response

  • Vaccination Protocol: Immunization of mice with complex adenovirus (Ad)-based vaccine candidates (cAdVax vaccines) (Wang et al., 2006).
  • Vaccine Immune Response Type: VO_0003057
  • Description: Vaccination led to efficient production of both antibodies and cytotoxic T lymphocytes (CTL) specific to Musoke strain GP and Ci67 strain GP, respectively. Antibody responses were also shown to be cross-reactive across the MARV strains, but not cross-reactive to Ebola virus, a related filovirus. Additionally, three 1 x 10(8)pfu doses of vaccine vector were demonstrated to be safe in mice, as this did not lead to any detectable toxicity in liver or spleen (Wang et al., 2006).
References References References
Wang et al., 2006: Wang D, Schmaljohn AL, Raja NU, Trubey CM, Juompan LY, Luo M, Deitz SB, Yu H, Woraratanadharm J, Holman DH, Moore KM, Swain BM, Pratt WD, Dong JY. De novo syntheses of Marburg virus antigens from adenovirus vectors induce potent humoral and cellular immune responses. Vaccine. 2006 Apr 5; 24(15); 2975-86. [PubMed: 16530297 ].
Wang et al., 2006: Wang D, Schmaljohn AL, Raja NU, Trubey CM, Juompan LY, Luo M, Deitz SB, Yu H, Woraratanadharm J, Holman DH, Moore KM, Swain BM, Pratt WD, Dong JY. De novo syntheses of Marburg virus antigens from adenovirus vectors induce potent humoral and cellular immune responses. Vaccine. 2006 Apr 5; 24(15); 2975-86. [PubMed: 16530297 ].
Wang et al., 2006: Wang D, Schmaljohn AL, Raja NU, Trubey CM, Juompan LY, Luo M, Deitz SB, Yu H, Woraratanadharm J, Holman DH, Moore KM, Swain BM, Pratt WD, Dong JY. De novo syntheses of Marburg virus antigens from adenovirus vectors induce potent humoral and cellular immune responses. Vaccine. 2006 Apr 5; 24(15); 2975-86. [PubMed: 16530297 ].